Dantrolene Sodium for Injection | more>> or ds-iv.com

Dantrolene Sodium for Injection is indicated, along with appropriate supportive measures, for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. It is also indicated preoperatively and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. Malignant hyperthermia is life threatening and requires immediate medical attention and treatment.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. There have been reports of thrombophlebitis following administration of intravenous dantrolene. There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium. Please see complete prescribing information for Dantrolene Sodium for Injection.

FAQs              

For More information on Malignant Hyperthermia please visit The Malignant Hyperthermia Association of the United States (MHAUS).

In Development

Lofexidine Hydrochloride | more>>

Lofexidine (for treatment of opiate withdrawal symptoms) is an alpha-2-adrenergic agonist which was licensed from Britannia Pharmaceuticals, Ltd of the United Kingdom. Lofexidine is being developed in the United States as a non-addictive, non-opiate treatment to manage the often debilitating withdrawal symptoms that occur during opiate detoxification. Lofexidine is not currently approved in the US. In support of a new drug application (NDA), US WorldMeds recently completed a pivotal phase III clinical trial (USWM-001) to test the safety and efficacy of Lofexidine. Click here to view the press release on the initial findings from the phase III study. In 2009, US WorldMeds plans to submit an application to the Food and Drug Administration for the approval to market Lofexidine in the US.

To obtain information on Lofexidine, please call Kristen Marcum at (502) 714-7811.

This is the place to look for US WorldMeds latest product releases as well as others in development. Our passion lies in bringing necessary medicines to the people at the most affordable prices.

US WorldMeds is proud to be a leader in bringing quality pharmaceuticals to everyone possible. We want to help the healthcare community provide the highest quality of life to as many patients as possible.